An Entity of Type: agent, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

Signature BioScience Inc. was the first biotechnology company based in San Francisco. It was formed in 1998 but closed in 2003 due to lack of funding. Before Signature was dissolved, it had just completed Phase II trials on Digitoxin, which the company was pursuing as an anti-cancer compound. However, the company's core competency was developing biotechnology tools that would be used to identify highly qualified pre-clinical leads.

Property Value
dbo:abstract
  • Signature BioScience Inc. was the first biotechnology company based in San Francisco. It was formed in 1998 but closed in 2003 due to lack of funding. Before Signature was dissolved, it had just completed Phase II trials on Digitoxin, which the company was pursuing as an anti-cancer compound. However, the company's core competency was developing biotechnology tools that would be used to identify highly qualified pre-clinical leads. (en)
dbo:foundingYear
  • 1998-01-01 (xsd:gYear)
dbo:numberOfEmployees
  • 100 (xsd:nonNegativeInteger)
dbo:wikiPageID
  • 19722189 (xsd:integer)
dbo:wikiPageLength
  • 8687 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID
  • 1056833447 (xsd:integer)
dbo:wikiPageWikiLink
dbp:dissolved
  • 2003 (xsd:integer)
dbp:foundation
  • 1998 (xsd:integer)
dbp:industry
  • BioPharmaceutical Discovery and Development (en)
dbp:keyPeople
  • Mark McDade who was succeeded by Robert J. Zimmerman (en)
dbp:locationCity
  • San Francisco (en)
dbp:locationCountry
  • USA (en)
dbp:name
  • Signature BioScience (en)
dbp:numEmployees
  • approximately 100 (en)
dbp:type
  • Private (en)
dbp:wikiPageUsesTemplate
dcterms:subject
rdf:type
rdfs:comment
  • Signature BioScience Inc. was the first biotechnology company based in San Francisco. It was formed in 1998 but closed in 2003 due to lack of funding. Before Signature was dissolved, it had just completed Phase II trials on Digitoxin, which the company was pursuing as an anti-cancer compound. However, the company's core competency was developing biotechnology tools that would be used to identify highly qualified pre-clinical leads. (en)
rdfs:label
  • Signature BioScience (en)
owl:sameAs
prov:wasDerivedFrom
foaf:isPrimaryTopicOf
foaf:name
  • Signature BioScience (en)
is dbo:wikiPageRedirects of
is dbo:wikiPageWikiLink of
is foaf:primaryTopic of
Powered by OpenLink Virtuoso    This material is Open Knowledge     W3C Semantic Web Technology     This material is Open Knowledge    Valid XHTML + RDFa
This content was extracted from Wikipedia and is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License